QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.089839v1 315/2/711    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Porter, R. H. P. Articles by Malherbe, P. Search for Related Content PubMed PubMed Citation Articles by Porter, R. H. P. Articles by Malherbe, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

NEUROPHARMACOLOGY

Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity

Pharma Division, Discovery Research CNS (R.H.P.P., W.S., T.M.B., A.M., E.P., A.M., S.G., V.M., P.M.) and Chemistry (G.J., B.B., S.K., J.-U.P., J.W., E.V.), F. Hoffmann-La Roche, Basel, Switzerland

Fenobam [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea] is an atypical anxiolytic agent with unknown molecular target that has previously been demonstrated both in rodents and human to exert anxiolytic activity. Here, we report that fenobam is a selective and potent metabotropic glutamate (mGlu)5 receptor antagonist acting at an allosteric modulatory site shared with 2-methyl-6-phenylethynyl-pyridine (MPEP), the protypical selective mGlu5 receptor antagonist. Fenobam inhibited quisqualate-evoked intracellular calcium response mediated by human mGlu5 receptor with IC₅₀ = 58 ± 2 nM. It acted in a noncompetitive manner, similar to MPEP and demonstrated inverse agonist properties, blocking 66% of the mGlu5 receptor basal activity (in an over expressed cell line) with an IC₅₀ = 84 ± 13 nM. [³H]Fenobam bound to rat and human recombinant receptors with K_d values of 54 ± 6 and 31 ± 4 nM, respectively. MPEP inhibited [³H]fenobam binding to human mGlu5 receptors with a K_i value of 6.7 ± 0.7 nM, indicating a common binding site shared by both allosteric antagonists. Fenobam exhibits anxiolytic activity in the stress-induced hyperthermia model, Vogel conflict test, Geller-Seifter conflict test, and conditioned emotional response with a minimum effective dose of 10 to 30 mg/kg p.o. Furthermore, fenobam is devoid of GABAergic activity, confirming previous reports that fenobam acts by a mechanism distinct from benzodiazepines. The non-GABAergic activity of fenobam, coupled with its robust anxiolytic activity and reported efficacy in human in a double blind placebo-controlled trial, supports the potential of developing mGlu5 receptor antagonists with an improved therapeutic window over benzodiazepines as novel anxiolytic agents.

Address correspondence to: Dr. Richard Porter, F. Hoffmann-La Roche, PRBD-N, Bldg. 69/452, CH-4070 Basel, Switzerland. E-mail: richard.porter{at}roche.com

This article has been cited by other articles:

				E Berry-Kravis, D Hessl, S Coffey, C Hervey, A Schneider, J Yuhas, J Hutchison, M Snape, M Tranfaglia, D V Nguyen, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome J. Med. Genet., April 1, 2009; 46(4): 266 - 271. [Abstract] [Full Text] [PDF]

				R. J. Hagerman, E. Berry-Kravis, W. E. Kaufmann, M. Y. Ono, N. Tartaglia, A. Lachiewicz, R. Kronk, C. Delahunty, D. Hessl, J. Visootsak, et al. Advances in the Treatment of Fragile X Syndrome Pediatrics, January 1, 2009; 123(1): 378 - 390. [Abstract] [Full Text] [PDF]